The emerging pathogen Candida auris: A focus on the Middle-Eastern countries.
Antifungal susceptibility
C. auris
Candidemia
Middle-East
Mortality
Virulence
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Historique:
received:
26
12
2018
revised:
27
02
2019
accepted:
10
03
2019
pubmed:
20
4
2019
medline:
15
11
2019
entrez:
20
4
2019
Statut:
ppublish
Résumé
Recent emergence of Candida auris as a multidrug resistant fungal pathogen, associated with difficult-to-control nosocomial transmission and high mortality, raises serious concerns for public health. Since it was first reported from Japan in 2009, C. auris infections have been diagnosed in several countries from all over the world. However, there is a paucity of reported cases from the Middle East. Literature search resulted in finding only six countries (Kuwait, Israel, Oman, KSA, UAE and Iran) reporting C. auris infections in the past three years. All patients were adults with several underlying comorbidities. Majority of the cases presented with bloodstream infection with crude mortality rate of 60%. All isolates were misidentified as C. haemulonii by commercial systems requiring specialized methods for identification. In vitro antifungal susceptibility testing showed 100% strains to be resistant to fluconazole (MIC 32 ≥ 256 mg/L) while variable resistance against other antifungal agents.
Identifiants
pubmed: 31000491
pii: S1876-0341(19)30118-2
doi: 10.1016/j.jiph.2019.03.009
pii:
doi:
Substances chimiques
Antifungal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-459Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.